Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy vTv Therapeutics stock
Learn how to easily invest in vTv Therapeutics stock.
vTv Therapeutics Inc is a biotechnology business based in the US. vTv Therapeutics shares (VTVT) are listed on the NASDAQ and all prices are listed in US Dollars. vTv Therapeutics employs 9 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in vTv Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VTVT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
vTv Therapeutics stock price (NASDAQ: VTVT)Use our graph to track the performance of VTVT stocks over time.
vTv Therapeutics shares at a glance
|Latest market close||$0.72|
|52-week range||$0.38 - $2.27|
|50-day moving average||$0.63|
|200-day moving average||$0.96|
|Wall St. target price||$4.17|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.25|
Buy vTv Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy vTv Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
vTv Therapeutics price performance over time
|1 week (2022-06-28)||-5.30%|
|1 month (2022-06-03)||1.41%|
|3 months (2022-04-01)||N/A|
|6 months (2022-01-04)||-28.00%|
|1 year (2021-07-02)||-67.57%|
|2 years (2020-07-02)||-68.28%|
|3 years (2019-07-05)||1.43|
|5 years (2017-07-05)||5.17|
vTv Therapeutics financials
|Revenue TTM||$5 million|
|Gross profit TTM||$-8,619,000|
|Return on assets TTM||-75.34%|
|Return on equity TTM||-335.49%|
|Market capitalisation||$55.7 million|
TTM: trailing 12 months
vTv Therapeutics share dividends
We're not expecting vTv Therapeutics to pay a dividend over the next 12 months.
vTv Therapeutics share price volatility
Over the last 12 months, vTv Therapeutics's shares have ranged in value from as little as $0.382 up to $2.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while vTv Therapeutics's is -1.4043. This would suggest that vTv Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, vTv Therapeutics has bucked the trend.
vTv Therapeutics overview
vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc.
Frequently asked questionsWhat percentage of vTv Therapeutics is owned by insiders or institutions?
Currently 70.336% of vTv Therapeutics shares are held by insiders and 7.796% by institutions. How many people work for vTv Therapeutics?
Latest data suggests 9 work at vTv Therapeutics. When does the fiscal year end for vTv Therapeutics?
vTv Therapeutics's fiscal year ends in December. Where is vTv Therapeutics based?
vTv Therapeutics's address is: 3980 Premier Drive, High Point, NC, United States, 27265 What is vTv Therapeutics's ISIN number?
vTv Therapeutics's international securities identification number is: US9183851057 What is vTv Therapeutics's CUSIP number?
vTv Therapeutics's Committee on Uniform Securities Identification Procedures number is: 918385105
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert